AVITA Medical Inc (ASX: AVH) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

AVITA Medical Inc Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $168.47 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 152.47 million
Earnings per share -0.362
Dividend per share N/A
Year To Date Return 0.48%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • AVITA Medical Inc (ASX: AVH)
    Latest News

    a woman
    Share Gainers

    Why AVITA, De Grey, Fortescue, & TPG Telecom shares are racing higher

    Fortescue Metals Group Limited (ASX:FMG) and TPG Telecom Ltd (ASX:TPM) shares are racing higher on Thursday. Here's why...

    Read more »

    a woman
    Share Market News

    Why the AVITA Medical share price is storming 7% higher today

    The AVITA Medical Ltd (ASX:AVH) share price is storming higher on Thursday after releasing an update on a study for…

    Read more »

    a woman
    Share Gainers

    Why Asaleo Care, Avita Medical, NEXTDC, & Northern Star are storming higher

    Avita Medical Ltd (ASX:AVH) and NEXTDC Ltd (ASX:NXT) are two of four storming notably higher today despite the market selloff.…

    Read more »

    a woman
    Share Market News

    Why the Avita Medical share price is rising 5% higher today

    The Avita Medical Ltd (ASX:AVH) share price is soaring 5% higher today as the S&P/ASX 200 Index (INDEXASX: XJO) recovers…

    Read more »

    a woman
    Share Gainers

    Afterpay and these ASX 200 shares are up over 80% in 12 months

    Afterpay Ltd (ASX:APT) and these ASX 200 shares have been on fire over the last 12 months. Here's why they are up…

    Read more »

    a woman
    Share Market News

    Avita Medical shares pop 5% on strong half year sales

    Avita Medical Ltd (ASX: AVH) shares are up more than 5% today following the release of its half year report…

    Read more »

    a woman
    Share Gainers

    Why these 4 ASX 200 shares are up 25% in February

    Check out why these 4 ASX 200 shares including Breville Group Ltd (ASX: BRG) have rocketed 25% higher or more…

    Read more »

    a woman
    Share Market News

    3 ASX events you missed on Friday

    A recap of the top things you missed on Friday as the S&P/ASX 200 (INDEXASX: XJO) finished the week on…

    Read more »

    a woman
    Healthcare Shares

    Why I think Avita Medical shares are a buy in 2020

    Avita Medical Limited (ASX: AVH) experienced over 700% share price growth in 2019, resulting in a market cap of $1.66…

    Read more »

    a woman
    Share Market News

    Why these 3 ASX shares surged higher today

    While the S&P/ASX 200 Index (INDEXASX: XJO) ended the day slightly down, here are 3 ASX shares that have shown…

    Read more »

    a woman
    Share Market News

    PolyNovo share price rises as CEO plans aggressive growth

    The Polynovo Ltd (ASX: PNV) share price has been on a tear this year, up more than 56% so far.…

    Read more »

    a woman
    Share Gainers

    Why AVITA, Bigtincan, Link, & ResMed shares are storming higher

    The Bigtincan Holdings Ltd (ASX:BTH) share price and the ResMed Inc. (ASX:RMD) share price are two of four ending the…

    Read more »

    Frequently Asked Questions

    No, AVITA Medical does not pay dividends at this time.

    AVITA Medical Inc listed on the ASX on 24 June 2020.

    Yes, as well as being listed on the ASX, AVITA Medical Inc is listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.

    AVH ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About AVITA Medical Inc

    AVITA Medical Inc (ASX: AVH) is a healthcare company specialising in regenerative medicine. It is best known for its RECELL system, a burn treatment device that creates 'spray-on skin' from a patient's own skin cells within 30 minutes, avoiding or reducing the need for skin grafts.

    The product was originally invented and patented by Western Australian doctor and clinical professor Fiona Wood in 1993. 

    RECELL is approved for use in Australia, Europe, Canada, China, the Middle East, and Africa. It is also approved for treating adult patients in the US. As well as burns, AVITA Medical has evidence of RECELL's effectiveness for additional skin applications, such as treating chronic and traumatic wounds, scar revision, and vitiligo. 

    AVITA Medical Inc is domiciled and also listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.

    AVH Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    14 Jan 2026 $1.11 $0.08 7.84% 898,919 $1.06 $1.13 $1.05
    13 Jan 2026 $1.02 $-0.03 -2.84% 334,574 $1.06 $1.06 $1.02
    12 Jan 2026 $1.06 $0.05 4.98% 560,041 $1.03 $1.09 $1.03
    09 Jan 2026 $1.01 $-0.04 -3.85% 681,993 $1.02 $1.03 $1.01
    08 Jan 2026 $1.04 $0.00 0.00% 535,148 $1.00 $1.05 $1.00
    07 Jan 2026 $1.05 $-0.02 -1.89% 287,685 $1.05 $1.08 $1.05
    06 Jan 2026 $1.06 $-0.05 -4.50% 367,839 $1.08 $1.09 $1.06
    05 Jan 2026 $1.11 $0.01 0.91% 308,745 $1.09 $1.12 $1.08
    02 Jan 2026 $1.10 $0.05 4.76% 400,753 $1.06 $1.12 $1.06
    31 Dec 2025 $1.05 $0.01 0.96% 255,932 $1.06 $1.10 $1.05
    30 Dec 2025 $1.05 $-0.02 -1.89% 109,413 $1.06 $1.07 $1.05
    29 Dec 2025 $1.06 $0.00 0.00% 111,071 $1.06 $1.07 $1.05
    24 Dec 2025 $1.06 $0.01 0.95% 172,811 $1.06 $1.07 $1.04
    23 Dec 2025 $1.06 $-0.02 -1.87% 326,883 $1.08 $1.08 $1.04
    22 Dec 2025 $1.07 $0.03 2.87% 161,124 $1.05 $1.09 $1.05
    19 Dec 2025 $1.05 $0.03 2.97% 223,986 $1.02 $1.05 $1.02
    18 Dec 2025 $1.01 $-0.02 -1.94% 180,845 $1.03 $1.03 $1.00
    17 Dec 2025 $1.03 $0.02 1.97% 141,494 $1.02 $1.03 $1.01
    16 Dec 2025 $1.02 $-0.02 -1.93% 312,310 $1.04 $1.05 $1.02

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    16 Oct 2025 James Corbett Exercise 2,891 $4,712
    Conversion of securities. As per announcement
    16 Oct 2025 James Corbett Buy 2,891 $4,712
    Conversion of securities. As per announcement
    29 Aug 2025 Robert McNamara Buy 10,000 $45,000
    On-market trade. USD $
    20 Aug 2025 Robert McNamara Buy 10,000 $50,000
    On-market trade. USD $, As per announcement on 27-08-2025
    06 Jun 2025 Robert McNamara Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Robert McNamara Exercise 9,200 $16,606
    Conversion of securities. 16,938 RSUs
    06 Jun 2025 Cary Vance Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Cary Vance Exercise 9,200 $16,606
    Conversion of securities. 16,938 RSUs
    06 Jun 2025 Louis (Lou) Panaccio Exercise 9,200 $16,606
    Conversion of securities. 10,022 RSUs
    06 Jun 2025 Louis (Lou) Panaccio Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Suzanne Crowe Issued 9,200 $16,606
    Conversion of securities. 22,990 CDIs
    06 Jun 2025 Suzanne Crowe Exercise 9,200 $16,606
    Conversion of securities. 10,022 RSUs
    06 Jun 2025 Jeremy Curnock-Cook Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Jeremy Curnock-Cook Exercise 9,200 $16,606
    Conversion of securities. 10,022 RSUs
    06 Jun 2025 Jan Reed Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Jan Reed Exercise 9,200 $16,606
    Conversion of securities. 12,913 RSUs
    05 Jun 2025 James Corbett Issued 520,000 $951,600
    Issue of options.
    05 Jun 2025 Louis (Lou) Panaccio Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 Louis (Lou) Panaccio Issued 10,022 $18,340
    Issue of securities. 19,222 RSUs
    05 Jun 2025 Jan Reed Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 Jan Reed Issued 10,022 $18,340
    Issue of securities. 22,113 RSUs
    05 Jun 2025 Jeremy Curnock-Cook Issued 10,022 $18,340
    Issue of securities. 19,222 RSUs
    05 Jun 2025 Jeremy Curnock-Cook Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 Suzanne Crowe Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 Suzanne Crowe Issued 10,022 $18,340
    Issue of securities. 19,222 RSUs
    05 Jun 2025 Robert McNamara Issued 10,022 $18,340
    Issue of securities. 26,138 RSUs
    05 Jun 2025 Robert McNamara Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 Cary Vance Issued 10,022 $18,340
    Issue of securities. 26,138 RSUs
    05 Jun 2025 Cary Vance Issued 4,295 $7,859
    Issue of options.
    07 Mar 2025 Robert McNamara Buy 11,000 $91,300
    On-market trade. USD$
    21 Feb 2025 Robert McNamara Buy 10,000 $100,900
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Professor Suzanne Crowe Non-Executive Director Jan 2016
    Ms Crowe is a physician-scientist and ASX/Nasdaq-listed company director with expertise in supporting companies with their medical and scientific strategies. She is currently a Director of Sonic Healthcare Ltd, a large global medical diagnostics company. Past board positions include St. Vincent's Health Australia Ltd (2012-2021), the country's largest not-for-profit health and aged care provider. After 35 years at both, she has recently retired from the Burnet Institute, having served as Associate Director Clinical Research, and The Alfred Hospital Melbourne, where she held the appointment of Senior Specialist Physician in Infectious Diseases. She was appointed as Officer of the Order of Australia in June 2020 in recognition of her services to health, clinical governance, biomedical research, and education.
    Mr Jeremy Curnock-Cook Non-Executive Director Oct 2012
    Mr Cook is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years. Founder and Managing Director of BioScience Managers, Mr. Curnock Cook brings his international experience to our Board of Directors. Over his career, Mr. Curnock Cook has successfully managed more than US $1 billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. Mr. Curnock Cook founded a European-focused seed fund with Johnson & Johnson and built the International Biotechnology Trust. Mr. Curnock Cook has served on more than 40 boards of directors in the life science sector in the UK, Europe, USA, Canada, Japan and Australia.
    Ms Jan Stern Reed Non-Executive Director Jul 2021
    Ms Reed has more than 35 years of legal, management and business leadership experience primarily within the healthcare industry, and brings expertise in corporate governance, compliance, and risk management. Ms. Reed served as Senior Vice President, General Counsel and Corporate Secretary at Walgreens Boots Alliance, Inc., a global health and wellbeing company. Prior to Walgreens, Ms. Reed was Executive Vice President, Human Resources, General Counsel and Corporate Secretary of Solo Cup Company, where she was responsible for the legal, human resources, internal audit, corporate communications, and compliance functions.
    Mr Cary Vance Non-Executive DirectorNon-Executive ChairmanInterim CEO Apr 2023
    Mr Vance brings over 25 years of executive leadership experience across the global healthcare industry, with a in transformative medical technologies. He previously held CEO roles at PhotoniCare, Inc., Titan Medical, XCath, OptiScan Biomedical, Myoscience, and Hansen Medical. Earlier in his career, he held senior leadership positions at Teleflex, Covidien, and GE HealthCare. Mr Vance is Lean/Six Sigma Black Belt Certified.
    Mr Robert McNamara Non-Executive Director Apr 2023
    Mr McNamara is a senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His experience in operations and financial management spans across early stage, high growth, and mature companies. He is a former member of the Board of Directors and Chair of Audit Committee for Axonics, Inc. Additionally, Mr. McNamara is a member of the Board of Directors, Chair of the Compensation Committee, and member of the Audit Committee for Xtant Medical Holdings. Prior to these appointments, Mr. McNamara served as Executive Vice President, Chief Financial Officer of LDR Holding/Spine. Prior to this role, he served as the Chief Financial Officer of three publicly traded medical device companies including Accuray, Somnus Medical Technologies, and Target Therapeutics.
    Dr Michael Eric Tarnoff Non-Executive Director Aug 2025
    Mr Tarnoff, spent 23 years at Tufts Medical Center in various executive roles, recently as Chief Physician Executive and CEO until 2024. He also served as Chief Medical Officer and Vice President, Medical Affairs at Medtronic from 2015 to 2019. From 2008 to 2015, he was corporate Chief Medical Officer and Vice President at Covidiens Surgical Devices division. His earlier roles include Medical Director at GI Dynamics (2006-2008) and Chief Medical Consultant at Tyco Healthcare (2005-2008).
    Mr Joseph(Joe) Fralin Woody Non-Executive Director Jan 2026
    Mr Woody is a healthcare executive with more than two decades of leadership experience across the medical technology sector, recently serving as CEO of Avanos Medical from 2017 to 2024, and previously, as President and CEO of Acelity Holdings. His background spans multiple senior executive roles, including with Covidien and Smith & Nephew. Across his storied professional career, Mr Woody also served on the Board of Directors of AdvaMed, Inc., the trade association in the U.S. for the medical device, diagnostics, and digital health technology sectors, for over a decade
    Mr Mark Andrew Licciardo Company Secretary Mar 2018
    -
    Ms Nicole Linda Kelsey Chief Legal and Compliance OfficerCompany Secretary Jul 2024
    -
    David O'Toole Chief Financial Officer
    -
    Nicole Linda Kelsey Chief Legal and Compliance OfficerCompany Secretary
    -
    Mark Andrew Licciardo Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Washington H Soul Pattinson And Company Limited 392,529 1.49%
    Citicorp Nominees Pty Limited 391,741 1.49%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 388,055 1.47%
    UBS Nominees Pty Ltd 345,782 1.31%
    Abn Amro Clearing Sydney Nominees Pty Ltd <Custodian A/C> 177,865 0.67%
    Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> 177,013 0.67%
    JP Morgan Nominees Australia Pty Limited 113,074 0.43%
    HSBC Custody Nominees (Australia) Limited 112,967 0.43%
    Taggart Investments Pty Ltd <Taggart Investment A/C> 86,000 0.33%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 76,729 0.29%
    Ioof Investment Services Limited <Ips Superfund A/C> 71,116 0.27%
    Neweconomy Com Au Nominees Pty Limited <900 Account> 70,808 0.27%
    BNP Paribas Nominees Pty Ltd <Clearstream> 70,704 0.27%
    HSBC Custody Nominees (Australia) Limited i 65,237 0.25%
    HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> 61,465 0.23%
    Mr Andre Wall Ellis & Mrs Olivia Louise Ellis 60,000 0.23%
    Mrs Arlene Perry 60,000 0.23%
    Wairahi Investments Limited 60,000 0.23%
    Mr David Anthony Deelen 57,200 0.22%
    Dental Union Of Australia Pty Ltd <Ian Weatherlake S/F A/C> 56,000 0.21%

    Profile

    since

    Note